News Merck & Co., Inc.

Equities

MRK

US58933Y1055

Pharmaceuticals

Market Closed - Nyse Other stock markets 21:01:20 21/05/2026 BST			5-day change	1st Jan Change
115.88 ^USD	+2.55%		+2.17%	+10.08%

05-20	National Advertising Review Board refers Merck animal health to FTC & FDA for Bravecto Quantum dosing claims	RE
05-20	Pharma sector doubles down on AI amid hopes of slashing costs, timelines	RE

All News

Mentions Relevance

05-20	National Advertising Review Board refers Merck animal health to FTC & FDA for Bravecto Quantum dosing claims	RE
05-19	Exelixis, Inc. Announces Clinical Development Collaboration with Merck for Phase 3 Stellar-316 Pivotal Trial for Patients with Colorectal Cancer	CI
05-19	International health experts meet in search for Ebola Bundibugyo vaccine options	RE
05-18	Regeneron drops after skin cancer treatment fails late-stage trial	RE
05-18	Merck Says Endometrial Cancer Therapy Meets Primary Endpoints in Phase 3 Trial	MT
05-18	Merck's drug helps uterine cancer patients live longer in late-stage trial	RE
05-18	Merck's endometrial cancer drug meets late-stage trial goals	RE
05-18	Merck announces TroFuse-005 trial evaluating sacituzumab tirumotecan met primary endpoints of overall survival and progression-free survival in certain patients with advanced or recurrent endometrial cancer	RE
05-18	Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer	BU
05-18	Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan Meets Primary Endpoints in Advanced or Recurrent Endometrial Cancer	CI
05-18	Regeneron drops after skin cancer treatment misses late-stage trial goal	RE
05-12	Merck highlights new long-term data and advancements across broad oncology portfolio and pipeline research at Asco 2026	RE
05-12	Merck Highlights New Long-Term Data and Advancements Across Broad Oncology Portfolio and Pipeline Research at ASCO 2026	BU
05-12	Merck Highlights New Long-Term Data and Advancements Across Broad Oncology Portfolio and Pipeline Research At Asco 2026	CI
05-08	Merck : Statement on Daiichi Sankyo Update to Manufacturing and Supply Plan - Merck.com	PU
05-07	Merck Scientists Publish Landmark Paper on Novel Method for Large-Scale Biocatalytic Synthesis of Investigational Oral PCSK9 Inhibitor, Enlicitide Decanoate	BU
05-05	Merck Completes Terns Pharmaceuticals Acquisition	MT
05-05	Merck Completes Acquisition of Terns Pharmaceuticals, Inc.	BU
05-01	Goldman Sachs Adjusts Merck Price Target to $137 From $133	MT
05-01	Wells Fargo Adjusts Merck Price Target to $145 From $150	MT
05-01	Morgan Stanley Raises Price Target on Merck to $112 From $109, Keeps Equalweight Rating	MT
04-30	Merck beats quarterly sales expectations as Keytruda fuels growth	RE
04-30	Merck Q1 adjusted loss per share $1.28 versus IBES estimate $-1.51	RE
04-30	Merck posts quarterly loss due to Cidara charge, sales rise 5%	RE
04-30	Merck & Co., Inc., Q1 2026 Earnings Call, Apr 30, 2026